Preclinical Models of Parkinson’s Disease

AAV α-synuclein over-expressing rodent

α-Synuclein is the major constituent protein of aggregates in Lewy bodies, the pathological hallmark of Parkinson’s disease. Viral delivery of α-synuclein to the substantia nigra of rats or mice produces a slowly developing degeneration of dopaminergic neurons in the substantia nigra with behavioural deficits and molecular pathology analogous to that observed in people with Parkinson’s disease. 

  • Disease-relevant mechanism of dopaminergic degeneration 
  • Can be used to assess disease modifying therapies 
  • Slowly developing rodent model of Parkinson’s disease

Model Overview

AAV1/2-hA53T-α-synuclein vectors are injected unilaterally into the substantia nigra of rats or mice using stereotaxic techniques. Degeneration of dopaminergic neurons occurs over several weeks allowing test compounds to be evaluated for disease modifying potential.

Slice through the rat brain showing the substantia nigra (marked by the yellow line) that has been stained with markers for three different proteins; green = α-synuclein, red = dopaminergic neurons, blue = all neurons.

  • Cells staining cyan = co-localisation of α-synuclein stain + neuronal stain
  • Cells staining magenta = co-localisation of dopaminergic neuron stain + neuronal stain
  • Cells staining yellow = co-localisation of α-synuclein stain + dopaminergic stain
  • Cells staining white = co-localisation of α-synuclein stain + dopaminergic neuron stain + neuronal stain

Robust loss on dopaminergic endpoints

Dopaminergic cell loss develops over time so that at 6 weeks post-surgery there is a 35-45% loss of striatal dopamine (right) and tyrosine hydroxylase positive cells (left) in the substantia nigra.

AAV-α-synuclein produces forelimb asymmetry that can be prevented by pharmacological intervention

Six weeks post-surgery, rats exhibit a pronounced forelimb asymmetry. Once daily treatment with trehalose, a known autophagy enhancer, completely prevents the development of forelimb asymmetry. This demonstrates that the model is able to identify compounds that can slow the progression of symptoms in the model.

AAV-α-synuclein-induced loss of dopamine can be prevented by pharmacological intervention

Six weeks post-surgery, rats exhibit a pronounced loss of striatal dopamine. Once daily treatment with trehalose significantly reduces the striatal dopamine loss demonstrating that the underlying pathological changes that occur in the model can be modified by pharmacological intervention.

Experimental readouts

  • Behavioural – Behaviour is assessed by a cylinder test that examines forelimb asymmetry. The limb asymmetry indicates an imbalance in striatal dopaminergic function between the side injected with AAV1/2-A53T-α-synuclein and the contralateral side. 
  • Post-mortem – Routine post-mortem analyses include striatal dopamine, striatal α-synuclein expression and the number of tyrosine hydroxylase positive cells in the substantia nigra. Additional post-mortem measures can be incorporated at the request of the client.
  • Target engagement – Demonstration of target engagement can often be incorporated into the study design aiding translation from rodent studies to non-human primate studies and ultimately to clinical studies.
  • Imaging – We offer both MRI and PET imaging that allows longitudinal measurement of markers of dopaminergic function and metabolism. Imaging can also be used to demonstrate target engagement.
  • Pharmacokinetics – Can be incorporated into all studies. Blood can be sampled throughout the study and terminal samples of CSF and brain and other tissues can be collected.

Related papers

Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease

Rhonda L. McFleder, Anastasiia Makhotkina, Janos Groh, Ursula Keber, Fabian Imdahl, Josefina Peña Mosca, Alina Peteranderl, Jingjing Wu, Sawako Tabuchi, Jan Hoffmann, Ann-Kathrin Karl, Axel Pagenstecher, Jörg Vogel, Andreas Beilhack, James B. Koprich, Jonathan M. Brotchie, Antoine-Emmanuel Saliba, Jens Volkmann, Chi Wang Ip

Nature Communications34 citations10.1038/s41467-023-43224-z

Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice

Akua A. Karikari, Rhonda L. McFleder, Eliana Ribechini, Robert Blum, Valentin Bruttel, Susanne Knorr, Mona Gehmeyr, Jens Volkmann, Jonathan M. Brotchie, Fadhil Ahsan, Beatrice Haack, Camelia-Maria Monoranu, Ursula Keber, Rima Yeghiazaryan, Axel Pagenstecher, Tobias Heckel, Thorsten Bischler, Jörg Wischhusen, James B. Koprich, Manfred B. Lutz, Chi Wang Ip

Brain, Behavior, and Immunity110 citations10.1016/j.bbi.2022.01.007

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism

Jacqueline A. Gleave, Lindsay R. Arathoon, Dennison Trinh, Kristin E. Lizal, Nicolas Giguère, James H.M. Barber, Zainab Najarali, M. Hassan Khan, Sherri L. Thiele, Mahin S. Semmen, James B. Koprich, Jonathan M. Brotchie, James H. Eubanks, Louis-Eric Trudeau, Joanne E. Nash

Neurobiology of Disease57 citations10.1016/j.nbd.2017.06.009

我们的位置与设施

世界级设施,全球化连接

我们的合作伙伴受益于国际认可的科学家团队以及运用尖端技术在加拿大与中国的实验平台上开展项目。

Atuka 是全球在非人灵长类动物(NHP)研究领域的专家,拥有 AAALAC 认证的现代化苏州设施,可同时开展多达 150 只猴的大型研究项目。我们能够在保障最高动物福利标准的前提下,完成其他 CRO 无法执行的复杂研究。

中国苏州

  • 猴体内研究设施
  • 影像学服务
  • 外科手术服务
  • 生物分析服务
  • 行为学研究服务

加拿大多伦多

  • 啮齿类体内研究设施
  • 体外实验室
  • 行政办公室

Talk to our experts

赋能您的研发项目

获取来自 Atuka 的最新科学进展

订阅我们的季刊,了解帕金森疾病研究领域的最新进展。

注册清单